Kura Oncology rises after US FDA approves its blood cancer therapy

Shares of drugmaker Kura Oncology KURA.O rise 1.03% to $10.79 in early trading

The U.S. Food and Drug Administration says has approved Komzifti, a new treatment from Kura, for adults with a rare and hard-to-treat form of blood cancer called acute myeloid leukemia or AML

The medicine is taken as a once-daily pill - FDA

Approval based on study of 112 adults; about 20% see cancer disappear or improve significantly, regulator says

FDA warns of serious side effects, including heart rhythm problems and risks to unborn babies

Including session's move, stock up ~24% YTD